Medicines access advocates have welcomed the licensing deal signed this month by the US National Institutes of Health with two global organizations for 11 innovative COVID-19 products, saying that the political significance of the move “cannot be ignored.”
The deal struck between the NIH, the World Health Organization’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) on 12 May is a very important one, according...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?